Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis

Xin, Yiqiao; Manson, Jan; Govan, Lindsay; Harbour, Robin; Bennison, Jenny; Watson, Eleanor; Wu, Olivia

doi:10.1186/s12876-016-0491-7

Table 5 Characteristics of systematic reviews comparing PPI and H₂ receptor antagonists (H₂RAs) (n = 3)

From: Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis

Author, year, country	Last search date	Disease	H₂RAs	PPI	No. of studies in MA	No. of patients in MA	Eradication rates by ITT	Eradication rates odds ratio (95 % CI) by ITT	Quality assessment^a
Gisbert et al. 2003 Spain [40]	Jan 2002	HP infection; naïve to treatment; PUD/NUD	H₂RAs (ranitidine/famotidine/nizatidine)+	PPI (ome/lanso)+	20	2374	69 % vs. 74 %	Triple vs. H ₂ RAs 1.31 (1.09-1.58)	+
Gisbert et al. 2003 Spain [40]	Jan 2002	HP infection; naïve to treatment; PUD/NUD	+ two same antibiotics (amoxicillin/clarithromycin/metronidazole/tinidazole) +/− bismuth-		20	2374	69 % vs. 74 %	Triple vs. H ₂ RAs 1.31 (1.09-1.58)	+
Graham et al. 2003 US [53]	1990–2001 (Published date)	HP infection; either naïve or with previous treatment failures	H₂RAs(nizatidine/famotidine/ranitidine) +	PPI (lanso/ome) +	12	1441	78 % vs. 81 %	0.83 (0.63–1.09)	0
			+ two same antibiotics (clarithromycin/amoxicillin/metronidazole/tinidazole)		12	1441	78 % vs. 81 %	0.83 (0.63–1.09)
			H₂RAs(not specified)+	Clarithromycin-containing triple : Clarithromycin + PPI(not specified)+	6	Not reported	79 % vs. 69 %	1.14 (0.76–1.71)
			+ one same antibiotics (not specified)		6	Not reported	79 % vs. 69 %	1.14 (0.76–1.71)
			H₂RAs(not specified)+	Clarithromycin NOT-containing triple: PPI(not specified)+	6	Not reported	78 % vs. 85 %	0.64 (0.45–0.92)
			+two same antibiotics (not specified)		6	Not reported	78 % vs. 85 %	0.64 (0.45–0.92)
Ren et al. 2010 China [41]	Apr 2010	HP infection; naïve to treatment	Lafutidine-containing: H₂RAs(lafutidine)+	Lanso-containing triple: PPI(lanso) +	3	238	78 % vs. 77.5 %	1.03 (0.64–1.66)	++
Ren et al. 2010 China [41]	Apr 2010	HP infection; naïve to treatment	+ two same antibiotics (clarithromycin + amoxicillin)		3	238	78 % vs. 77.5 %	1.03 (0.64–1.66)	++

HP H.pylori, H2RAs H2 receptor antagonists, PPI proton pump inhibitor, esome esomeprazole, lanso lansoprazole, ome omeprazole, panto pantoprazole, rabe rabeprazole, PUD peptic ulcer disease, NUD non-ulcer dyspepsia, MA meta-analysis, ITT intention to treat, CI confidence interval, RCT randomized controlled trials
^a Quality assessment: high quality (++): majority of criteria met, little or no risk of bias and results unlikely to be changed by further research. Acceptable (+): most criteria met, some flaws in the study with an associated risk of bias and conclusions may change in the light of further studies. Low quality (0): either most criteria not met or significant flaws relating to key aspects of study design, and conclusions likely to change in the light of further studies

Back to article page

ISSN: 1471-230X

Contact us

Submission enquiries: bmcgastroenterology@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Gastroenterology

Contact us